| The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: Comparison with the National Cancer Institute‐Common … G Cavaletti, B Frigeni, F Lanzani, M Piatti, S Rota, C Briani, G Zara, ... Journal of the Peripheral Nervous System 12 (3), 210-215, 2007 | 302 | 2007 |
| Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale G Cavaletti, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, ... Neurology 61 (9), 1297-1300, 2003 | 231 | 2003 |
| Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-L-carnitine G Bianchi, G Vitali, A Caraceni, S Ravaglia, G Capri, S Cundari, C Zanna, ... European journal of cancer 41 (12), 1746-1750, 2005 | 203 | 2005 |
| A pilot study on the effect of acetyl-L-carnitine in paclitaxel-and cisplatin-induced peripheral neuropathy A Maestri, A de Pasquale Ceratti, S Cundari, C Zanna, E Cortesi, L Crinò Tumori Journal 91 (2), 135-138, 2005 | 180 | 2005 |
| Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy G Cavaletti, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, ... Annals of Oncology 15 (9), 1439-1442, 2004 | 145 | 2004 |
| Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity G Cavaletti, C Zanna European Journal of Cancer 38 (14), 1832-1837, 2002 | 120 | 2002 |
| A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations MH Voss, C Hierro, RS Heist, JM Cleary, F Meric-Bernstam, J Tabernero, ... Clinical Cancer Research 25 (9), 2699-2707, 2019 | 113 | 2019 |
| Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties O Ghirardi, PL Giudice, C Pisano, M Vertechy, A Bellucci, L Vesci, ... Anticancer research 25 (4), 2681-2687, 2005 | 101 | 2005 |
| Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised … XS Sun, Y Tao, C Le Tourneau, Y Pointreau, C Sire, MC Kaminsky, ... The Lancet Oncology 21 (9), 1173-1187, 2020 | 95 | 2020 |
| Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale B Frigeni, M Piatti, F Lanzani, P Alberti, P Villa, C Zanna, M Ceracchi, ... Journal of the peripheral nervous system 16 (3), 228-236, 2011 | 84 | 2011 |
| Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study H Herbert, S David, P Henry, B Jeffrey, C Rashmi, R Elisabeth, R Joseph, ... Cancer Chemotherapy Pharmacology 75, 851-859, 2015 | 72 | 2015 |
| The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma O Matzinger, D Viertl, P Tsoutsou, L Kadi, S Rigotti, C Zanna, ... Radiotherapy and Oncology 116 (3), 495-503, 2015 | 64 | 2015 |
| FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... Cancer discovery 11 (10), 2488-2505, 2021 | 51 | 2021 |
| Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia—results … JF DiPersio, HP Erba, RA Larson, SM Luger, MS Tallman, JM Brill, ... Clinical Lymphoma Myeloma and Leukemia 15 (7), 443-449, 2015 | 45 | 2015 |
| Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors C Sessa, S Cresta, T Cerny, J Baselga, ER Caremoli, A Malossi, D Hess, ... Annals of oncology 18 (3), 561-568, 2007 | 34 | 2007 |
| IART®: Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation G Paganelli, M Ferrari, M Cremonesi, C De Cicco, V Galimberti, A Luini, ... The Breast 16 (1), 17-26, 2007 | 30 | 2007 |
| Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. JM Cleary, G Iyer, DY Oh, IK Mellinghoff, L Goyal, MCH Ng, ... Journal of Clinical Oncology 38 (15_suppl), 3603-3603, 2020 | 27 | 2020 |
| Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer G Paganelli, M Ferrari, L Ravasi, M Cremonesi, C De Cicco, V Galimberti, ... Clinical Cancer Research 13 (18), 5646s-5651s, 2007 | 25 | 2007 |
| FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. DM Hyman, L Goyal, P Grivas, F Meric-Bernstam, J Tabernero, Y Hu, ... Journal of Clinical Oncology 37 (15_suppl), TPS3157-TPS3157, 2019 | 21 | 2019 |
| Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design J Bourhis, B Burtness, LF Licitra, C Nutting, JD Schoenfeld, M Omar, ... Future Oncology 18 (14), 1669-1678, 2022 | 20 | 2022 |
